sorafenib has been researched along with azd 6244 in 22 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (azd 6244) | Trials (azd 6244) | Recent Studies (post-2010) (azd 6244) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 477 | 80 | 423 |
| Protein | Taxonomy | sorafenib (IC50) | azd 6244 (IC50) |
|---|---|---|---|
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 0.014 | |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.4845 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 19 (86.36) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Chong, LW; Chow, P; Chung, A; Huynh, H; Koong, HN; Lam, WL; Lee, J; Lee, SS; Lew, GB; Ngo, VC; Ong, HS; Ong, WJ; Soo, KC; Thng, CH; Yang, S | 1 |
| Choo, SP; Chow, P; Chung, A; Goh, BC; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Poon, D; Smith, PD; Soo, KC; Thng, CH; Toh, HC | 1 |
| Chang, CJ; Chao, CH; Chen, CT; Hortobagyi, GN; Hsu, JM; Hung, MC; Woodward, WA; Xia, W; Xie, X; Yang, JY | 1 |
| Friedrich, MJ | 1 |
| Agarwal, K; Brendel, VJ; Jarjoura, D; Koh, YW; Koo, BS; McCarty, SK; Porter, K; Ringel, MD; Saji, M; Shah, MH; Wang, C | 1 |
| Abell, AN; Chen, X; Darr, DB; Duncan, JS; Earp, HS; Frye, SV; Gomez, SM; Granger, DA; Graves, LM; He, X; Hoadley, KA; Jin, J; Johnson, GL; Johnson, NL; Jordan, NV; Kim, WY; Kuan, PF; Major, B; Midland, AA; Nakamura, K; Perou, CM; Sharpless, NE; Smalley, DM; Usary, J; Whittle, MC; Zawistowski, JS; Zhou, B | 1 |
| Cheng, CW; Chong, TW; Huynh, H; Lau, WK; Ong, RW; Sim, HG; Sim, MY; Yuen, JS | 1 |
| Lin, CI; Lorch, JH; Ruan, DT; Whang, EE | 1 |
| Barone, M; Carr, BI; Di Leo, A; Facciorusso, A; Licinio, R | 1 |
| Ghosh, AK; Giroux, V; Jossé, R; Luo, J; Pommier, Y; Zhang, YW | 1 |
| Blüthgen, N; Brummer, T; Fritsche-Guenther, R; Kempa, S; Sers, C; Witzel, F | 1 |
| Choo, SP; Goh, BC; Hartano, S; Huynh, H; Koh, TS; Lim, C; Lim, KT; Low, LS; Ng, QS; Tai, WM; Tham, CK; Thng, CH; Toh, HC; Wang, LZ; Wang, WW; Yong, WP | 1 |
| Anderson, DG; Conte, D; Fischer, A; Hough, S; Kennedy, Z; Li, Y; Moore, J; Mou, H; Park, A; Pomyen, Y; Song, CQ; Thorgeirsson, S; Wang, XW; Weng, Z; Xue, W; Yin, H; Zender, L | 1 |
| Bardeesy, N; Benes, CH; Chang, CC; Chang, CF; Chen, Y; Dima, S; Duda, DG; Duyverman, AM; Flaherty, KT; Gao, DY; Hsu, FF; Huang, P; Jain, RK; Jeng, KS; Kitahara, S; Lin, TT; Liu, CH; Liu, YC; Popescu, I; Ramjiawan, RR; Sung, YC; Zhu, AX | 1 |
| Lim, SY; Menzies, AM; Rizos, H | 1 |
| Goh, KY; Huynh, H; Lee, LY; Mumberg, D; Ong, R; Politz, O; Puehler, F; Scholz, A; Ziegelbauer, K | 1 |
| Brown, SR; Buckley, HL; Du, Y; Farnell, K; Flanagan, L; Flux, G; Gonzalez de Castro, D; Gregory, R; Hall, A; Moss, L; Newbold, K; Wadsley, J | 1 |
3 review(s) available for sorafenib and azd 6244
| Article | Year |
|---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2015 |
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2017 |
2 trial(s) available for sorafenib and azd 6244
| Article | Year |
|---|---|
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2016 |
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
Topics: Antineoplastic Agents; Benzimidazoles; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Metastasis; Phenylurea Compounds; Quinolines; Sorafenib; Thyroid Neoplasms; United Kingdom | 2019 |
17 other study(ies) available for sorafenib and azd 6244
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Blotting, Western; Disease Models, Animal; Drug Synergism; Humans; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms | 2009 |
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.
Topics: Animals; Benzenesulfonates; Benzimidazoles; beta Catenin; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Centrosome; Chromosome Aberrations; DNA Breaks, Double-Stranded; DNA Damage; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Models, Biological; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Polycomb Repressive Complex 2; Proto-Oncogene Proteins c-raf; Pyridines; Rad51 Recombinase; Signal Transduction; Sorafenib; Spheroids, Cellular; Transcription Factors; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidazoles; Carcinoma; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Survival; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Sirolimus; Sorafenib; Thyroid Neoplasms; TOR Serine-Threonine Kinases | 2012 |
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Breast Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Kinase 1; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proteome; Proto-Oncogene Proteins c-myc; Pyridines; Receptor Protein-Tyrosine Kinases; Sorafenib | 2012 |
Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney Neoplasms; Mice; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Processing, Post-Translational; Pyridines; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Tumor Burden; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Benzimidazoles; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Immunosuppressive Agents; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms | 2012 |
Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Chromatin; Chromosomes; Embryo, Mammalian; Fibroblasts; Humans; Macrolides; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Porifera; Proto-Oncogene Proteins c-raf; Sorafenib | 2015 |
Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
Topics: Apoptosis; Benzimidazoles; Blotting, Western; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2016 |
Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Topics: Animals; Benzimidazoles; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; CRISPR-Cas Systems; Cytoskeletal Proteins; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Neurofibromatosis 1; Genome-Wide Association Study; Hepatocytes; High-Throughput Nucleotide Sequencing; HMGA Proteins; HMGA2 Protein; Humans; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Membrane Glycoproteins; Mice; Mice, Knockout; Mice, Nude; Mitogen-Activated Protein Kinases; Nerve Tissue Proteins; Niacinamide; Nitriles; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridones; Pyrimidinones; ras Proteins; Real-Time Polymerase Chain Reaction; Receptors, Cell Surface; Sequence Analysis, DNA; Sorafenib; Survival Analysis; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2017 |
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Topics: Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line; Drug Delivery Systems; Humans; Liver Neoplasms; Mice; Nanoparticles; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib | 2017 |
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Sorafenib; Sulfonamides; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2019 |